+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Chronic Urticaria Or Hives Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

  • ID: 4830075
  • Drug Pipelines
  • August 2019
  • Region: Global
  • 65 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Allakos Inc
  • Faes Farma SA
  • Genentech Inc
  • JDP Therapeutics Inc
  • Mycenax Biotech Inc
  • Roche
  • MORE
High levels of pipeline activity are being observed in Chronic Urticaria Or Hives treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Allakos Inc, ELORAC Inc, Faes Farma SA, Fountain Biopharma Inc, Genentech Inc and others.

A Significant contribution to the Chronic Urticaria Or Hives pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Chronic Urticaria Or Hives pipeline included 14 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Chronic Urticaria Or Hives condition and increased access to investments is encouraging growth of Chronic Urticaria Or Hives drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Chronic Urticaria Or Hives drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Chronic Urticaria Or Hives therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Chronic Urticaria Or Hives pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Chronic Urticaria Or Hives. Further, orphan drug status, fast track designation, grants awarded and other special status for Chronic Urticaria Or Hives pipeline compounds are also included.

This study was produced independently by the publisher from their proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Chronic Urticaria Or Hives pipeline and formulate effective research and development strategies.

Research Methodology

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Chronic Urticaria Or Hives Pipeline candidates
  • Pre-clinical Phase: Discovery, research, pre-clinical
  • Early Phase: Phase 1 and Phase 2 Chronic Urticaria Or Hives drugs
  • Late phase: Phase 3 and in-approval Chronic Urticaria Or Hives drugs
Companies involved in the Pipeline
  • Company overview
  • Snapshot
  • Chronic Urticaria Or Hives therapeutic treatment activities
Details for each Chronic Urticaria Or Hives drug candidate
  • Snapshot
  • Drug Name
  • Alternative Names
  • Company
  • Originator
  • Phase
  • Molecule Type
  • Orphan Drug Status
  • Drug Overview
  • Mechanism of Action
  • Current Status
  • Trial Details
Other details
  • Pre-clinical trials for each drug candidate
  • Clinical trials for each drug candidate
Recent Chronic Urticaria Or Hives therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allakos Inc
  • Faes Farma SA
  • Genentech Inc
  • JDP Therapeutics Inc
  • Mycenax Biotech Inc
  • Roche
  • MORE
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Chronic Urticaria Or Hives- Disease Overview
2.2 Chronic Urticaria Or Hives- Pipeline Snapshot
2.3 Chronic Urticaria Or Hives- Pipeline Drugs by Phase
2.4 Chronic Urticaria Or Hives- Pipeline Drugs by Company
2.5 Chronic Urticaria Or Hives- Pipeline Drugs by Mechanism of Action

3 Company wise Pipeline Analysis
3.1 Allakos Inc Chronic Urticaria Or Hives Drug Pipeline, H2- 2019
3.2 ELORAC Inc Chronic Urticaria Or Hives Drug Pipeline, H2- 2019
3.3 Faes Farma SA Chronic Urticaria Or Hives Drug Pipeline, H2- 2019
3.4 Fountain Biopharma Inc Chronic Urticaria Or Hives Drug Pipeline, H2- 2019
3.5 Genentech Inc Chronic Urticaria Or Hives Drug Pipeline, H2- 2019
3.6 GlaxoSmithKline Plc Chronic Urticaria Or Hives Drug Pipeline, H2- 2019
3.7 Glenmark Pharmaceuticals Ltd Chronic Urticaria Or Hives Drug Pipeline, H2- 2019
3.8 JDP Therapeutics Inc Chronic Urticaria Or Hives Drug Pipeline, H2- 2019
3.9 JHL Biotech Inc Chronic Urticaria Or Hives Drug Pipeline, H2- 2019
3.10 Mycenax Biotech Inc Chronic Urticaria Or Hives Drug Pipeline, H2- 2019
3.11 Novartis AG Chronic Urticaria Or Hives Drug Pipeline, H2- 2019
3.12 Roche Chronic Urticaria Or Hives Drug Pipeline, H2- 2019
3.13 Synermore Biologics Co Ltd Chronic Urticaria Or Hives Drug Pipeline, H2- 2019
3.14 United BioPharma Inc Chronic Urticaria Or Hives Drug Pipeline, H2- 2019

4 Phase 1 Pipeline Drug Details
4.1 Chronic Urticaria Or Hives- Phase 1 Drug Details
4.2 Chronic Urticaria Or Hives- Phase 1 Drug Overview
4.3 Chronic Urticaria Or Hives- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details

5 Phase 2 Pipeline Drug Details
5.1 Chronic Urticaria Or Hives- Phase 2 Drug Details
5.2 Chronic Urticaria Or Hives- Phase 2 Drug Overview
5.3 Chronic Urticaria Or Hives- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details

6 Phase 3 Pipeline Drug Details
6.1 Chronic Urticaria Or Hives- Phase 3 Drug Details
6.2 Chronic Urticaria Or Hives- Phase 3 Drug Overview
6.3 Chronic Urticaria Or Hives- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details

7 Pre-clinical Phase Pipeline Drug Details
7.1 Chronic Urticaria Or Hives- Pre-clinical Phase Drug Details
7.2 Chronic Urticaria Or Hives- Pre-clinical Phase Drug Overview
7.3 Chronic Urticaria Or Hives- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details

8 Recent News and Developments

9 Appendix
9.1 About the Publisher
9.2 Sources and Research Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Allakos Inc
  • ELORAC Inc
  • Faes Farma SA
  • Fountain Biopharma Inc
  • Genentech Inc
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • JDP Therapeutics Inc
  • JHL Biotech Inc
  • Mycenax Biotech Inc
  • Novartis AG
  • Roche
  • Synermore Biologics Co Ltd
  • United BioPharma Inc
Note: Product cover images may vary from those shown
Adroll
adroll